BostonGene Corporation
BostonGene Corporation, headquartered in the United States, is a pioneering entity in the biotechnology industry, specialising in precision medicine and advanced genomic analysis. Founded in 2017, the company has rapidly established itself as a leader in the development of innovative solutions for cancer treatment, leveraging its proprietary algorithms and comprehensive data analytics. With a focus on personalised healthcare, BostonGene offers unique products and services that integrate genomic data with clinical insights, enabling tailored therapeutic strategies for patients. The company’s commitment to enhancing patient outcomes has garnered recognition within the healthcare community, positioning it as a key player in the evolving landscape of oncology. Through its cutting-edge technology and dedication to research, BostonGene continues to drive advancements in precision medicine, making significant strides in the fight against cancer.
DitchCarbon Score
How does BostonGene Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BostonGene Corporation's score of 25 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
BostonGene Corporation's reported carbon emissions
In 2023, BostonGene Corporation reported total carbon emissions of approximately 689,400,000 kg CO2e, with Scope 1 and 2 emissions accounting for about 259,000,000 kg CO2e and Scope 3 emissions at approximately 6,894,000,000 kg CO2e. This marks a reduction in Scope 1 and 2 emissions compared to previous years, where emissions were about 324,000,000 kg CO2e in 2022 and 327,000,000 kg CO2e in 2021. Over the years, BostonGene has shown a trend of decreasing Scope 1 and 2 emissions, while Scope 3 emissions have fluctuated, peaking at approximately 7,606,000,000 kg CO2e in 2018. Despite these reductions, the company has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. BostonGene's commitment to addressing climate change is evident through its emissions reporting, although further details on specific strategies or long-term goals remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - |
| Scope 2 | - | - | - | - | - | - | - |
| Scope 3 | 7,410,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BostonGene Corporation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
